The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000593336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/04/2026
Date registered
Help: Date registered
12/05/2026
Date last updated
Help: Date last updated
12/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A Safety and Feasibility Evaluation of a Novel Bronchoscopic Ultrasound Scope: The NOVUS Study - Phase 2
Scientific title
A Safety and Feasibility Evaluation of a Novel Bronchoscopic Ultrasound Scope: The NOVUS Study - Phase 2
Additional trial identifiers [1] 317089 0
Nil known
Universal Trial Number (UTN)
Trial acronym
The NOVUS Study (Phase 2)
Related trial records
This record is the Phase 2 study of ACTRN12626000117314 (Phase 1)

Health condition
Health condition(s) studied:
Lung Cancer 341612 0
Condition category
Condition code
Cancer 337691 337691 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This clinical investigation is a prospective, single-arm, single-centre, first-in-human study designed to evaluate the safety and feasibility of a new endobronchial ultrasound system for the survey and sampling of mediastinal and hilar lymph node stations.

The procedure is intended for patients with confirmed or suspected lung cancer who require lymph node staging; lymph node staging is a commonly performed and guideline recommended procedure to further characterize a patient’s lung cancer disease state. Conventional methods are performed using a manual bronchoscope (i.e., manual endobronchial ultrasound guided transbronchial-guided needle aspiration [EBUS-TBNA])

The study uses a new bronchoscopic ultrasound system, which integrates a live camera and ultrasound imaging to support the survey and sampling of lymph nodes.
The Lymph node stations of Phase 2 participants will be surveyed and biopsied/sampled using the investigational device.

All procedures are performed under general anaesthesia. The device is inserted via an airway access device and moved through the lungs by the physician according to navigation guidance provided by the study device to relevant lymph node stations for survey and sampling. The order and overall workflow of node assessment/sampling is at the clinician’s discretion. The Investigator may use conventional endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to complete sampling if instances occur in which the investigational device is unable to sample clinically indicated nodes/stations. Rapid on-site evaluation (ROSE) will be performed for all collected samples and will specify which device the sample was obtained from.

The full study procedure is expected to last approximately 30 mins to one hour. The procedure will take place in the bronchoscopy suite performed by qualified physicians which is similar to the practice for conventional lymph node staging and sampling. Representatives of the device manufacturer will be observing the procedure and will provide technical guidance regarding use of the device if needed.

Participants will be followed up at 1 week, 30 days and 3 months following the procedure by the study team. At the 1 week and 30-day follow-up visits the physician will discuss the results with patients and will review their medical records. At the 3-month follow-up visit, medical records will be reviewed to understand if any other interventions for lung cancer were performed during this period.

Adverse events will be collected through 30-days post procedure.
Intervention code [1] 333846 0
Diagnosis / Prognosis
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345172 0
Safety
Timepoint [1] 345172 0
Intra-procedure and at one week and 30-day follow-up, daily from day of procedure up to the 30-day follow-up period. Participants will be reviewed by medically trained personnel. In addition, medical records will be reviewed.
Primary outcome [2] 345173 0
Feasibility
Timepoint [2] 345173 0
Post-procedure once histopathological/cytological results become available. No fixed post-procedure time window is specified.
Secondary outcome [1] 460753 0
Nil
Timepoint [1] 460753 0
Nil

Eligibility
Key inclusion criteria
1. Subject is greater than or equal to 21 years old
2. Subjects must have a confirmed diagnosis of lung cancer or be assessed by the Investigator as having a high clinical suspicion and indicated for staging lung cancer
Minimum age
21 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Subjects with known significant pulmonary conditions, including but not limited to interstitial pneumonia, severe and symptomatic Chronic Obstructive Pulmonary Disease (COPD), diffuse symptomatic fibrosis of the lungs, severe respiratory failure, and/or pulmonary arterial hypertension, or those requiring home oxygen.
2. Subjects with severe cardiovascular conditions (such as myocardial infarction within 6 months of the procedure or uncontrolled cardiac arrhythmia) or severe cerebrovascular conditions (such as a history of stroke or Transient Ischemic Attack (TIA) within 6 months of the procedure).
3. Subjects with confirmed stage IV primary lung cancer prior to the start of the study procedure.
Subjects with current or active systemic infections, including acute viral, fungal, or bacterial diagnoses.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
A sample size of approximately 30 evaluable subjects is chosen to provide reasonable precision for the primary performance endpoint. As the study has no hypotheses, statistical power is not a consideration.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment postcode(s) [1] 45748 0
4006 - Herston

Funding & Sponsors
Funding source category [1] 321679 0
Commercial sector/Industry
Name [1] 321679 0
Ascend Clinical Research Organisation, Pty Ltd.
Country [1] 321679 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Ascend Clinical Research Organization, Pty Ltd.
Address
Country
Australia
Secondary sponsor category [1] 324503 0
None
Name [1] 324503 0
Address [1] 324503 0
Country [1] 324503 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320210 0
Metro North Health Human Research Ethics Committee
Ethics committee address [1] 320210 0
Ethics committee country [1] 320210 0
Australia
Date submitted for ethics approval [1] 320210 0
15/10/2025
Approval date [1] 320210 0
05/12/2025
Ethics approval number [1] 320210 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149774 0
A/Prof David Fielding
Address 149774 0
Royal Brisbane and Women's Hospital Butterfield Street, Herston QLD, 4006
Country 149774 0
Australia
Phone 149774 0
+61736464241
Fax 149774 0
Email 149774 0
Contact person for public queries
Name 149775 0
David Fielding
Address 149775 0
Royal Brisbane and Women's Hospital Butterfield Street, Herston QLD, 4006
Country 149775 0
Australia
Phone 149775 0
+61736464241
Fax 149775 0
Email 149775 0
Contact person for scientific queries
Name 149776 0
David Fielding
Address 149776 0
Royal Brisbane and Women's Hospital Butterfield Street, Herston QLD, 4006
Country 149776 0
Australia
Phone 149776 0
+61736464241
Fax 149776 0
Email 149776 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: IPD will not be available



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.